Trial Profile

A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 26 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sitravatinib (Primary)
Indications Bone metastases; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Prostate cancer; Renal cell carcinoma; Solid tumours
Focus Adverse reactions; First in man; Pharmacokinetics; Proof of concept
Sponsors MethylGene; Mirati Therapeutics

Most Recent Events

02 Mar 2023 Status changed from active, no longer recruiting to completed.
17 Nov 2022 Planned End Date changed from 1 Nov 2020 to 1 Dec 2022.
29 Jun 2022 Results (n=193) published in the Investigational New Drugs

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com